Chloroquine - Revision history

Lazy at 08:15, 18 January 2025

2025-01-18T08:15:46Z

← Older revision		Revision as of 01:15, 18 January 2025
Line 51:		Line 51:
	\|toxicity_explanation=		\|toxicity_explanation=
	\|toxicity_explanation=Chloroquine and Hydroxychloroquine are generally well-tolerated when used for glioblastoma treatment. Most studies observed minimal impact on the occurrence of adverse events. This implies that these drugs, especially Chloroquine, carry a low risk of causing harmful side effects or discomfort, therefore they are assigned the lowest toxicity level of 1.		\|toxicity_explanation=Chloroquine and Hydroxychloroquine are generally well-tolerated when used for glioblastoma treatment. Most studies observed minimal impact on the occurrence of adverse events. This implies that these drugs, especially Chloroquine, carry a low risk of causing harmful side effects or discomfort, therefore they are assigned the lowest toxicity level of 1.
	}}		\|overview=Chloroquine, in combination with traditional chemotherapy agents for glioblastoma treatment, has shown significant improvement in median survival rates, from 11 months with BCNU alone to 25-33 months when combined with chloroquine. While Chloroquine is well-tolerated with minimal adverse effects, Hydroxychloroquine has not demonstrated improved survival, indicating Chloroquine's potential as the more promising option for future clinical trials.}}

69.163.248.232 at 18:57, 12 November 2024

2024-11-12T18:57:48Z

← Older revision		Revision as of 11:57, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.		\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.
	\|~~treatment_treatment_treatment_treatment_category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|toxicity_level=1		\|toxicity_level=1
	\|book_text=Chloroquine and Hydroxychloroquine		\|book_text=Chloroquine and Hydroxychloroquine

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:21:48Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:21, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.		\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.
	\|~~treatment_treatment_treatment_category~~=Repurposed Drugs		\|treatment_treatment_treatment_treatment_category=Repurposed Drugs
	\|toxicity_level=1		\|toxicity_level=1
	\|book_text=Chloroquine and Hydroxychloroquine		\|book_text=Chloroquine and Hydroxychloroquine

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:16:04Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:16, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.		\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.
	\|~~treatment_treatment_category~~=Repurposed Drugs		\|treatment_treatment_treatment_category=Repurposed Drugs
	\|toxicity_level=1		\|toxicity_level=1
	\|book_text=Chloroquine and Hydroxychloroquine		\|book_text=Chloroquine and Hydroxychloroquine

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:15:01Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:15, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.		\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.
	\|~~treatment_category~~=Repurposed Drugs		\|treatment_treatment_category=Repurposed Drugs
	\|toxicity_level=1		\|toxicity_level=1
	\|book_text=Chloroquine and Hydroxychloroquine		\|book_text=Chloroquine and Hydroxychloroquine

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:13:28Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:13, 12 November 2024
Line 11:		Line 11:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.		\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.
	\|~~category~~=Repurposed Drugs		\|treatment_category=Repurposed Drugs
	\|toxicity_level=1		\|toxicity_level=1
	\|book_text=Chloroquine and Hydroxychloroquine		\|book_text=Chloroquine and Hydroxychloroquine

Lazy at 23:50, 27 March 2024

2024-03-27T23:50:05Z

← Older revision		Revision as of 16:50, 27 March 2024
Line 48:		Line 48:
	* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)		* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)
	* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)		* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)
			* [ study with TMZ] ( https://pubmed.ncbi.nlm.nih.gov/24991840/?dopt=Abstract)
	\|toxicity_explanation=		\|toxicity_explanation=
	\|toxicity_explanation=Chloroquine and Hydroxychloroquine are generally well-tolerated when used for glioblastoma treatment. Most studies observed minimal impact on the occurrence of adverse events. This implies that these drugs, especially Chloroquine, carry a low risk of causing harmful side effects or discomfort, therefore they are assigned the lowest toxicity level of 1.		\|toxicity_explanation=Chloroquine and Hydroxychloroquine are generally well-tolerated when used for glioblastoma treatment. Most studies observed minimal impact on the occurrence of adverse events. This implies that these drugs, especially Chloroquine, carry a low risk of causing harmful side effects or discomfort, therefore they are assigned the lowest toxicity level of 1.
	}}		}}

Lazy at 16:46, 27 March 2024

2024-03-27T16:46:01Z

← Older revision		Revision as of 09:46, 27 March 2024
Line 48:		Line 48:
	* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)		* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)
	* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)		* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)
			\|toxicity_explanation=
			\|toxicity_explanation=Chloroquine and Hydroxychloroquine are generally well-tolerated when used for glioblastoma treatment. Most studies observed minimal impact on the occurrence of adverse events. This implies that these drugs, especially Chloroquine, carry a low risk of causing harmful side effects or discomfort, therefore they are assigned the lowest toxicity level of 1.
	}}		}}

Lazy at 16:45, 27 March 2024

2024-03-27T16:45:50Z

← Older revision		Revision as of 09:45, 27 March 2024
Line 48:		Line 48:
	* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)		* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)
	* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)		* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)
	~~\|toxicity_explanation=~~
	}}		}}

Lazy at 16:31, 27 March 2024

2024-03-27T16:31:48Z

← Older revision		Revision as of 09:31, 27 March 2024
Line 12:		Line 12:
	\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.		\|notes=Recent studies highlight Chloroquine's potential in glioblastoma treatment, significantly improving survival rates when combined with chemotherapy. Chloroquine acts as an autophagy inhibitor, potentially enhancing chemotherapy's effectiveness by inhibiting a survival mechanism in cancer cells. Hydroxychloroquine's efficacy at the maximum tolerated dose has not shown improvement in survival, suggesting Chloroquine as the more promising agent for future clinical trials, especially considering tumor genetic profiles such as EGFR status.
	\|category=Repurposed Drugs		\|category=Repurposed Drugs
	\|toxicity_level=1 ~~or 2~~		\|toxicity_level=1
	\|book_text=Chloroquine and Hydroxychloroquine		\|book_text=Chloroquine and Hydroxychloroquine

Line 48:		Line 48:
	* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)		* [Chloroquine Supplementation for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies - PubMed](https://pubmed.ncbi.nlm.nih.gov/36409625)
	* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)		* [Chloroquine in Cancer Therapy: A Double-Edged Sword of Autophagy - AACR Journals](https://aacrjournals.org/cancerres/article/73/1/3/584147/Chloroquine-in-Cancer-Therapy-A-Double-Edged-Sword)
			\|toxicity_explanation=
	}}		}}